ReproCELL Incorporated operates two businesses centered on iPS cell-related technologies in regenerative medicine: research support and medical. It is advancing global operations using overseas bases and development aimed at product launches centered on three pipelines.
Since its founding in 2003, ReproCELL Incorporated has operated around two pillars, its research support business and medical business, based on iPS cell technology. Drawing on its accumulated embryonic stem cell technology, the company provides research reagents and drug discovery support while pursuing the commercialization of cell products, including neural and cardiac muscle cells. It listed on the JASDAQ market in 2013, now the Growth Market, and established the foundation for product launches following the development of the legal framework promoting regenerative medicine.
The company is working toward the launch of regenerative medicine products, centered on three pipelines beginning with ステムカイマル, a regenerative medicine product. Its development of iPS-derived neural glial cells aims to apply them to treatments for ALS and transverse myelitis and is currently at the animal testing stage. In cancer immunotherapy, the company is working with Keio University Hospital to prepare for the launch of tumor-infiltrating lymphocyte infusion therapy (TIL).
The company advanced its global expansion by acquiring companies in the United States and the United Kingdom in 2014. It has since integrated REPROCELL USA Inc. and REPROCELL Europe Ltd. to form an international business network. By incorporating overseas technologies and business models, it is accelerating the global rollout of its products.
Its growth strategy is to maximize synergies between the research support and medical businesses, with a particular focus on increasing the contribution of the medical business. As the Japanese market is relatively small, the company emphasizes expansion in overseas markets, primarily the United States and Europe. It is strengthening joint research with academic institutions and enhancing its technological capabilities through the adoption of new technologies, including cancer immunotherapy.